Vnitr Lek 2022, 68(8):508-512 | DOI: 10.36290/vnl.2022.108

Evolution of deep vein thrombosis treatment from leeches to mechanical thrombectomy

Jan Raupach¹, Jan Mašek¹, Vendelín Chovanec¹, Radovan Malý²

¹ Radiologická klinika LF UK a FN, Hradec Králové

² I. interní kardioangiologická klinika LF UK a FN, Hradec Králové

Deep vein thrombosis (DVT) is one of the most common diseases in developed countries with significant socioeconomic consequences. The severity of DVT lies in the potential for life-threatening pulmonary embolism and the development of chronic venous insufficiency, referred to as post-thrombotic syndrome. Virchow contributed to the understanding of the pathophysiological events that lead to thrombosis by describing three basic risk mechanisms. The first therapeutic attempts in the 17th century included venepuncture and the application of leeches. The first anticoagulant drug was heparin, which entered clinical practice after 1935. Subsequent commercialization of oral vitamin K antagonists (warfarin) and the advent of low molecular weight heparin along with compression therapy allowed the expansion of outpatient treatment of DVT. Recently, new oral anticoagulants have been introduced, leading to improved safety due to lower risk of bleeding complications and simplification of the treatment process. The next step in the development of therapeutic options are invasive methods of early thrombus removal, which significantly shorten the process and aim to reduce the occurrence of late complications. These methods include local catheter-directed thrombolysis using tissue plasminogen activator, mechanical thrombectomy and their combination called pharmaco-mechanical thrombectomy. The latter is currently used in patients with acute ilio-femoral DVT.

Keywords: deep vein thrombosis, thrombolysis, thrombectomy.

Accepted: December 1, 2022; Published: December 6, 2022  Show citation